Safety, Tolerability, and Efficacy of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Phase 3, Multicenter, 24-week, Open-label Study (P10-15.010)

John Rothrock; Umer Najib; Jessica Ailani; Sait Ashina; Jia Bao; Jonathan D. Smith; Iryna Shakhmantsir; Brett Dabruzzo; Kimberly Pfleeger; Andrew M. Blumenfeld

doi:10.1212/wnl.0000000000215534

June 9, 2026Neurology

Safety, Tolerability, and Efficacy of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Phase 3, Multicenter, 24-week, Open-label Study (P10-15.010)

View at Publisher

Ask AI

Bookmark

Share

Key Points

The research aims to assess the safety, tolerability, and efficacy of atogepant when added to onabotulinumtoxinA for chronic migraine prevention.
Phase 3, multicenter, open-label trial
Participants received atogepant alongside onabotulinumtoxinA
Trial duration was 24 weeks
Results demonstrate improved efficacy in chronic migraine prevention with the combination treatment
Findings suggest increased tolerability and safety with atogepant added to onabotulinumtoxinA

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Phase 3 trial evaluates safety and efficacy of atogepant plus onabotulinumtoxinA for chronic migraine prevention, indicating potential benefits.

Abstract

Evaluate the safety, tolerability, and efficacy of adding atogepant to onabotulinumtoxinA (onabotA) for the preventive treatment of chronic migraine (CM).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rothrock et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf36efaef96ed7f055e2f https://doi.org/10.1212/wnl.0000000000215534

View at Publisher

Ask AI

Bookmark

Share

Safety, Tolerability, and Efficacy of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Phase 3, Multicenter, 24-week, Open-label Study (P10-15.010)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Safety, Tolerability, and Efficacy of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Phase 3, Multicenter, 24-week, Open-label Study (P10-15.010)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading